Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

38.54 -0.8

Buy Sell

Overview

Share price change

24h

Current

Min

37.61

Max

39.36

Key metrics
By Trading Economics
Income	10M 32M
Sales	-28M 215M
P/E Sector Avg	14.355 68.51
EPS	0.79
Profit margin	15.084
Employees	293
EBITDA	-2.8M 49M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+7.35% upside

Dividends
By Acuity
Next Earnings	3 lis 2026

Market Stats
By TradingEconomics
Market Cap	175M 2.1B
Previous open	39.34
Previous close	38.54

News Sentiment

By Acuity

94%

5 / 340 Ranking in Healthcare

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 sie 2026, 20:04 UTC

Social Media

News

Event

Harmony Biosciences reported strong Q2 earnings of $75.43 million and reaffirmed 2026 revenue guidance, with shares trading sharply higher during the session.

3 sie 2026, 23:11 UTC

Harmony Biosciences shares are higher in after-hours trading, supported by positive sentiment from the Institute for Supply Management's manufacturing PMI report.

1 sie 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 lip 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 lip 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 lip 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 lip 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 lip 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 lip 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

7.35% upside

12 Months Forecast

Average 41.63 USD 7.35%

High 55 USD

Low 30 USD

Based on 8 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Sentiment

By Acuity

5 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.